Edinburgh, UK, 3rd May 2018 / Synpromics Ltd, the leader in gene control, today announced it has been awarded a £1.9m research and development grant from
Edinburgh, UK, 23rd April 2018 / Synpromics Ltd, the leader in gene control, announces a partnership with Lonza Pharma & Biotech to further develop its inducibl
The research and development agreement will develop synthetic promoters for use in immune system cells including lymphoid, myeloid and microglia cells.
Synpromics announces the appointment of Sarah Haecker Meeks, PhD to the position of Vice President, Business Development.
Synpromics collaborates with UCL to generate a range of synthetic gene promoters for the CNS to develop a gene therapy for Parkinson’s disease.